GlobeNewsWire · IVVD · October 21, 2026

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

Get the app for more

Explore stock news, insights and company research.